Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
The Cancer Clinic, St. Olav's University Hospital, Trondheim, Norway.
Eur J Haematol. 2021 Apr;106(4):529-536. doi: 10.1111/ejh.13581. Epub 2021 Feb 10.
In contrast to secondary primary malignancies (SPM) following multiple myeloma (MM), less is known about previous malignancies. We therefore conducted a population-based study to assess the patterns of previous malignancies in MM patients as well as the risk for SPM.
Using data from the Cancer Registry of Norway, we included 9574 MM patients and 37 810 matched control subjects. The association between previous malignancies and a subsequent diagnosis of MM was analysed by a logistic regression model and the risk for SPM by a Cox model.
A previous diagnosis of myeloproliferative neoplasia (MPN) (OR 3.57; 95% CI:1.45-8.80) and Hodgkin lymphoma (HL) (OR 3.66; 95% CI: 1.40-9.55) was associated with the subsequent development of MM. For MPN, the association with MM was explained by an excess of primary myelofibrosis (PMF) in the MM group. The overall incidence of a previous malignancy was not different between MM patients and the control subjects (OR 0.93; 95% CI: 0.87-1.00). MM patients had an increased risk for secondary acute myelogenous leukaemia/myelodysplastic syndromes (HR 6.1, 95% CI: 3.9-9.5).
A previous diagnosis of HL and PMF was associated with a subsequent diagnosis of MM, whereas the overall incidence of previous cancers was not increased for MM patients.
与多发性骨髓瘤（MM）后的继发性原发性恶性肿瘤（SPM）相比，人们对先前恶性肿瘤的了解较少。因此，我们进行了一项基于人群的研究，以评估 MM 患者先前恶性肿瘤的模式以及 SPM 的风险。
我们使用来自挪威癌症登记处的数据，纳入了 9574 名 MM 患者和 37810 名匹配的对照者。通过逻辑回归模型分析先前恶性肿瘤与随后诊断为 MM 之间的关联，并通过 Cox 模型分析 SPM 的风险。
先前诊断为骨髓增生性肿瘤（MPN）（OR 3.57；95%CI：1.45-8.80）和霍奇金淋巴瘤（HL）（OR 3.66；95%CI：1.40-9.55）与随后发生 MM 相关。对于 MPN，与 MM 的关联可归因于 MM 组中原发性骨髓纤维化（PMF）的过多。MM 患者和对照者之间先前恶性肿瘤的总体发生率无差异（OR 0.93；95%CI：0.87-1.00）。MM 患者发生继发性急性髓系白血病/骨髓增生异常综合征的风险增加（HR 6.1，95%CI：3.9-9.5）。
先前诊断为 HL 和 PMF 与随后诊断为 MM 相关，而 MM 患者的总体先前癌症发生率并未增加。
